Novo Nordisk open to New York listing upgrade, CEO Doustdar tells FT
23/09/2026 05:11
Novo Nordisk open to New York listing upgrade, CEO Doustdar tells FT Sept 23 (Reuters) - Novo Nordisk NOVOb.CO is open to the idea of upgrading its New York listing as part of efforts to raise the Danish weight-loss drugmaker's profile in the country, its chief executive told Financial Times in an interview published on Wednesday.
"I clearly do see some advantages with that," CEO Mike Doustdar told the newspaper when asked whether Novo would consider a direct listing on the New York Stock Exchange, replacing the American depositary receipts that currently provide U.S. investors access to the stock.
(Reporting by Rishabh Jaiswal in Bengaluru; Editing by Sherry Jacob-Phillips)
((rishabh.jaiswal@thomsonreuters.com; +91 9916719147))
Recent news on Novo Nordisk A/S
See all newsFocus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Factbox: Anthropic's public benefit fund and how it compares with other big philanthropic efforts
Novo's CagriSema helped women lose 25% of weight on average, analysis shows
As weight-loss drug users turn to dietary supplements, doctors, regulators raise flags
Factbox: Major drugmakers turn to China for licensing deals